Anixa Biosciences Inc (NASDAQ:ANIX) Given Consensus Rating of “Moderate Buy” by Brokerages

Anixa Biosciences Inc (NASDAQ:ANIX) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.50.

A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th.

Anixa Biosciences Trading Down 3.9%

Shares of NASDAQ:ANIX opened at $3.42 on Friday. The business has a 50-day moving average price of $2.97 and a 200 day moving average price of $2.93. The company has a market capitalization of $116.35 million, a price-to-earnings ratio of -11.03 and a beta of 0.59. Anixa Biosciences has a 12-month low of $2.32 and a 12-month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. As a group, equities research analysts predict that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar acquired 21,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average cost of $2.50 per share, with a total value of $52,500.00. Following the completion of the purchase, the chief executive officer owned 630,812 shares of the company’s stock, valued at $1,577,030. This represents a 3.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders acquired 45,024 shares of company stock valued at $131,621 over the last ninety days. Insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors have recently bought and sold shares of ANIX. Marshall Wace LLP acquired a new stake in shares of Anixa Biosciences during the second quarter worth about $39,000. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences in the second quarter valued at approximately $33,000. Jane Street Group LLC grew its holdings in shares of Anixa Biosciences by 37.2% in the second quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock valued at $138,000 after purchasing an additional 11,340 shares in the last quarter. Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences in the second quarter worth $37,000. Finally, Vanguard Group Inc. increased its position in shares of Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after acquiring an additional 29,436 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.